<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://www.gourt.com/Health/Pharmacy.html">
<title>Pharmacy RSS : Gourt</title>
<link>http://www.gourt.com/Health/Pharmacy.html</link>
<description></description>
<dc:language>en-us</dc:language>
<dc:rights>Copyright 2007, Gourt.com</dc:rights>
<dc:date>2009-11-06T22:55+08:00
</dc:date>
<dc:publisher>rtruog@gourt.com</dc:publisher>
<dc:creator>rtruog@gourt.com</dc:creator>
<dc:subject>Pharmacy RSS : Gourt</dc:subject>
<syn:updatePeriod>hourly</syn:updatePeriod>
<syn:updateFrequency>1</syn:updateFrequency>
<syn:updateBase>1901-01-01T00:00+00:00</syn:updateBase>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/170128.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/170084.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/170093.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/170038.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/170039.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/170041.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/170046.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169934.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169936.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169911.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169880.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169888.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169863.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169849.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169811.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169749.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169746.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169697.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169672.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169564.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169567.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169552.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169553.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169554.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169562.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/170086.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/170085.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169899.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169643.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169627.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169458.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169369.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169240.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169139.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169127.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168946.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/169004.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168869.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168830.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168696.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168531.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168447.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168349.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168316.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168302.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168270.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168156.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168202.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/168126.php" />
  <rdf:li rdf:resource="http://www.medicalnewstoday.com/articles/167938.php" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189436.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189400.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189311.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189295.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189081.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189394.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188750.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188748.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188717.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188715.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188708.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188543.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188768.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188776.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188374.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188305.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188266.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187966.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187813.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187174.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm189402.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189400.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm189296.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188981.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm188971.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm188954.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm188912.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm188929.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm188578.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm188570.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm188628.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188562.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm188321.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm188521.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm188318.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm188156.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm188137.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm187979.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm187973.htm" />
  <rdf:li rdf:resource="http://www.fda.gov/Safety/Recalls/ucm187949.htm" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://www.medicalnewstoday.com/articles/170128.php">
<title>Ag Biotech Industry Stands Behind IRM Program</title>
<link>http://www.medicalnewstoday.com/articles/170128.php</link>
<description><![CDATA[The agricultural biotechnology industry maintains that the Insect Resistance Management (IRM) Plan has been one of the most successful industry stewardship programs implemented since pest-tolerant biotech crops were introduced more than a decade ago.      A report released today by the Center for Science in the Public Interest (CSPI) alleges that farmer compliance with the insect-resistance management requirement has declined somewhat in recent years.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/170084.php">
<title>DOJ Investigates Alleged Fraud By Drugmakers; Sanctions On WellCare Lifted</title>
<link>http://www.medicalnewstoday.com/articles/170084.php</link>
<description><![CDATA[News outlets focus on alleged fraud in the drug and insurance industries. "A $112 million settlement involving alleged drug kickbacks that the Justice Dept. announced with the nation's largest nursing home pharmacy and a generic drug manufacturer on Nov. 3 is part of a wide-ranging investigation of suspected Medicaid fraud by the pharmaceutical industry," ]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/170093.php">
<title>Wall Street Journal Examines Big Pharma&#x27;s &#x27;Growing Interest&#x27; In Emerging-Market Vaccine Development, Production</title>
<link>http://www.medicalnewstoday.com/articles/170093.php</link>
<description><![CDATA[The Wall Street Journal examines "big pharma's growing interest in a corner of healthcare - emerging-market inoculations," in light of a recent move by Novartis to purchase an 85 percent stake in the Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical Co.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/170038.php">
<title>Helix BioPharma Corp. Completes Enrollment In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts</title>
<link>http://www.medicalnewstoday.com/articles/170038.php</link>
<description><![CDATA[Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) announced that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial.    The double-blind and placebo-controlled Phase II trial is underway at multiple centers in Germany and Sweden.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/170039.php">
<title>Pivotal Data Published In The Journal Cancer Demonstrate That TREANDA Induced Durable Responses In Relapsed Indolent Non-Hodgkin&#x27;s Lymphoma</title>
<link>http://www.medicalnewstoday.com/articles/170039.php</link>
<description><![CDATA[Cephalon, Inc. (Nasdaq: CEPH) announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/170041.php">
<title>Amgen Announces Overall Survival Results For Vectibix(R) In First-Line Metastatic Colorectal Cancer</title>
<link>http://www.medicalnewstoday.com/articles/170041.php</link>
<description><![CDATA[Amgen (Nasdaq: AMGN) announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/170046.php">
<title>Sunesis&#x27; Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia</title>
<link>http://www.medicalnewstoday.com/articles/170046.php</link>
<description><![CDATA[Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169934.php">
<title>Man Sentenced For Sale And Supply Of Controlled And Counterfeit Drugs</title>
<link>http://www.medicalnewstoday.com/articles/169934.php</link>
<description><![CDATA[A 41-year-old man, Mr Harish Gami, received an eight month prison sentence suspended for two years at Aylesbury Crown Court today for the illicit sale and supply of controlled drugs as well as counterfeit and unlicensed medicines.   The Medicines and Healthcare products Regulatory Agency (MHRA) discovered more than 86,000 Valium tablets and a further 11,500 medicinal products in an undercover investigation into Gami's illegal online dealing.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169936.php">
<title>The Creation Of A New Niche Specialty Pharmaceutical Company Focused On Rare Diseases - With Strong Cash Flow Generation And Growth Potential</title>
<link>http://www.medicalnewstoday.com/articles/169936.php</link>
<description><![CDATA[Biovitrum and Swedish Orphan will be combined forming Swedish Orphan Biovitrum with pro forma revenues 2009 of approximately SEK 2 billion and an EBITDA margin of 15 percent. Biovitrum will pay an upfront consideration of SEK 3.5 billion (on a cash and debt free basis), to be financed by a fully guaranteed rights issue, an issue in kind and bank financing. The Transaction will be instantly accretive to earnings per share for Biovitrum's shareholders.   Shared mission.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169911.php">
<title>Conflicts Of Interest Examined Between Doctors And Medical Industry, AARP And Reform</title>
<link>http://www.medicalnewstoday.com/articles/169911.php</link>
<description><![CDATA[ Health care reform bills include provisions to examine the financial relationships between doctors and the medical industry while some are questioning the AARP's role in reform. ]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169880.php">
<title>ViraCor-IBT Laboratories To Present At The American College Of Allergy, Asthma And Immunology&#x27;s Annual Meeting</title>
<link>http://www.medicalnewstoday.com/articles/169880.php</link>
<description><![CDATA[Scientists from ViraCor-IBT Laboratories have been selected to provide four oral presentations and one poster presentation at this year's American College of Allergy, Asthma and Immunology's Annual Scientific Meeting in Miami, Florida. Michelle Altrich, PhD, HCLD (ABB), and Michael Ling, PhD, will present data on a wide range of topics including Filaggrin, Pneumococcal Antibody Avidity, Chronic Urticaria, Drug Hypersensitivity Reactions and T-Cell Excision Circles.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169888.php">
<title>FDA Unveils Safe Use Initiative That Targets Preventable Harm From Medication Use</title>
<link>http://www.medicalnewstoday.com/articles/169888.php</link>
<description><![CDATA[The U.S. Food and Drug Administration announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use.   "Too many people suffer unnecessary injuries from avoidable medication misuse, errors and other problems. The FDA is launching the Safe Use Initiative to develop targeted solutions for reducing these injuries," said FDA Commissioner Margaret A. Hamburg, M.D.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169863.php">
<title>Drug Company-sponsored Events For Health Professionals Fail To Disclose Financial Ties</title>
<link>http://www.medicalnewstoday.com/articles/169863.php</link>
<description><![CDATA[Australian reporting standards for disclosing the ties between      pharmaceutical companies and health professionals are not      comprehensive enough, according to an analysis in this weeks PLoS      Medicine.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169849.php">
<title>FDA Awards Absorption Systems Phase II SBIR Grant For CellPort Technologies&#x2122;</title>
<link>http://www.medicalnewstoday.com/articles/169849.php</link>
<description><![CDATA[Absorption Systems LP announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the U.S. Food and Drug Administration (FDA) to continue development of the company's CellPort Technologies™ testing platform. This unique assay platform enables more specific prediction of potential drug-drug interactions mediated by human drug transport proteins.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169811.php">
<title>GlaxoSmithKline, Pfizer Formally Launch Company To Develop New HIV Treatments</title>
<link>http://www.medicalnewstoday.com/articles/169811.php</link>
<description><![CDATA[ Pharmaceutical companies GlaxoSmithKline (GSK) and Pfizer on Tuesday formally launched ViiV Healthcare, a company focused on the development of new HIV treatments, Dow Jones Newswires/SmartMoney.com reports (11/3).]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169749.php">
<title>Study Points To New Uses, Unexpected Side Effects Of Already-existing Drugs</title>
<link>http://www.medicalnewstoday.com/articles/169749.php</link>
<description><![CDATA[Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs.    The researchers developed a computational method that compares how similar the structures of all known drugs are to the naturally occurring binding partners -- known as ligands -- of disease targets within the cell.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169746.php">
<title>Aerovance Completes Patient Enrollment In Phase 2b Clinical Trial Of Aerovant(TM) For Treatment Of Uncontrolled Asthma</title>
<link>http://www.medicalnewstoday.com/articles/169746.php</link>
<description><![CDATA[Aerovance Inc. announced it has completed patient enrollment in a Phase 2b clinical trial of the inhaled dry powder formulation of Aerovant for the treatment of uncontrolled asthma. Top-line results are expected by the second quarter of 2010.    Named AeroTrial(TM), the study enrolled approximately 540 patients at 75 sites in the United States and Europe.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169697.php">
<title>Experts Propose &#x27;Global Health Accellerator&#x27; To Help New Drugs, Diagnostics, Vaccines Reach Distant Markets</title>
<link>http://www.medicalnewstoday.com/articles/169697.php</link>
<description><![CDATA[Research firms in developing countries have a medicine cabinet full of affordable and innovative drugs, diagnostics and vaccines on shelves or in development to address "neglected tropical diseases" but need help to get such products to more potential users.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169672.php">
<title>MEPs And Industry Debate Shared Commitment To Deliver 21st Century Healthcare Systems In Times Of Crisis</title>
<link>http://www.medicalnewstoday.com/articles/169672.php</link>
<description><![CDATA[European policymakers and the pharmaceutical industry need to work collaboratively to ensure the current financial crisis does not stand in the way of delivering healthcare systems fit for the 21st century. Representatives of EFPIA, the voice of the research-based pharmaceutical industry in Europe, and MEPs involved in healthcare issues discussed a common agenda to shape the future of healthcare in Europe.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169564.php">
<title>Ocera Therapeutics Presents Clinical Data Demonstrating AST-120 Relieves Pruritus In Patients With Liver Cirrhosis At The 60th Annual AASLD Meeting</title>
<link>http://www.medicalnewstoday.com/articles/169564.php</link>
<description><![CDATA[Ocera Therapeutics, Inc. announced that AST-120 (spherical carbon adsorbent) was shown to reduce the severity of pruritus (itching) in patients with chronic liver disease. The data were presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases in a presentation titled, "Oral AST-120 (Spherical Carbon Adsorbent) Improves Pruritus and Lowers Serum Bile Acids in Patients with Cirrhosis of Various Etiologies.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169567.php">
<title>Sanofi Pasteur Presents Safety Data On Menactra(R) Vaccine Given To Infants At Infectious Disease Society Meeting</title>
<link>http://www.medicalnewstoday.com/articles/169567.php</link>
<description><![CDATA[Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), presented Safety of a Quadrivalent (A,C,Y,W-135) Meningococcal Vaccine When Given to Infants with Other Pediatric Vaccines at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) this past weekend.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169552.php">
<title>Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), An Investigational, Once-Daily Protease Inhibitor For Hepatitis C</title>
<link>http://www.medicalnewstoday.com/articles/169552.php</link>
<description><![CDATA[Schering-Plough Corporation (NYSE: SGP) reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169553.php">
<title>BioVex Announces Publication Of Phase 2 Melanoma Results With OncoVEX (GM-CSF) In The Journal Of Clinical Oncology</title>
<link>http://www.medicalnewstoday.com/articles/169553.php</link>
<description><![CDATA[BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169554.php">
<title>Amylin Pharmaceuticals And Eli Lilly And Company Statement On FDA&#x27;s BYETTA(R) (Exenatide) Injection Update</title>
<link>http://www.medicalnewstoday.com/articles/169554.php</link>
<description><![CDATA[Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA® (exenatide) injection.    "The FDA update issued today aligns with the BYETTA label approved last week. The current label reflects our understanding of post-marketing reports of renal events and provides physicians with updated guidance about appropriate use in patients with renal conditions.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169562.php">
<title>Quark Pharmaceuticals To Present Data On Its SiRNA Therapeutic Programs In Kidney And Lung Diseases</title>
<link>http://www.medicalnewstoday.com/articles/169562.php</link>
<description><![CDATA[Quark Pharmaceuticals, Inc., a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/170086.php">
<title>New FDA Program Targets Drug Dosage Errors</title>
<link>http://www.medicalnewstoday.com/articles/170086.php</link>
<description><![CDATA[ Federal Drug Administration Commissioner Margaret A. Hamburg announced a new "Safe Use" program for drugs on Wednesday. The program sets out "to reduce the misuse of medications, saying that at least 50,000 hospitalizations a year could be prevented if physicians, pharmacists, patients and parents used greater care in dispensing and taking drugs," ]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/170085.php">
<title>Consumers In Search Of Saving Money Should Reconsider Prescription Drug Choices</title>
<link>http://www.medicalnewstoday.com/articles/170085.php</link>
<description><![CDATA[ Americans are increasingly scrutinizing their drug choices to find ones that work but don't break the bank. The Associated Press reports: "Last year pharmaceutical companies spent more than $4 billion urging patients like you to 'ask your doctor' about their drugs.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169899.php">
<title>SHPA Support For Pharmacists&#x27; Support Service, Australia</title>
<link>http://www.medicalnewstoday.com/articles/169899.php</link>
<description><![CDATA[The Society of Hospital Pharmacists of Australia has announced financial support for   the Pharmacists' Support Service, a dedicated support and counseling service for   pharmacists who need assistance.       PSS, which is managed by the Pharmaceutical Society of Victoria, is soon to be made   available nationally and in light of this, the SHPA has donated $2000 to assist the   service in this transition phase.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169643.php">
<title>Pharmacists Positioned To Help Patients With Diabetes Management</title>
<link>http://www.medicalnewstoday.com/articles/169643.php</link>
<description><![CDATA[An estimated 1.8 million Canadians are currently living with diabetes and that number that is rapidly growing. Chronic diseases, like diabetes, put a huge burden on the Canadian health care system and the direct costs to the system, from diabetes alone, are expected to exceed $15 billion by next year.    Pharmacists play an important role in diabetes management and are positioned to take on even greater responsibilities.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169627.php">
<title>Over 7 Million UK Adults May Be Gambling Their Lives With Fake Medicine, UK</title>
<link>http://www.medicalnewstoday.com/articles/169627.php</link>
<description><![CDATA[More than one in seven British adults surveyed (15%)1   admitted to bypassing the healthcare system to get hold of prescription only medicine   without a prescription, a practice which 78% of GPs surveyed say is putting people's   health and potentially lives at risk3, as some of the medicines obtained in this way may   be counterfeit.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169458.php">
<title>New Tests For Identifying Potentially Deadly Adulterants In Pharmaceutical Ingredients</title>
<link>http://www.medicalnewstoday.com/articles/169458.php</link>
<description><![CDATA[To further protect patients from adulterated medicines, the U.S. Pharmacopeial Convention (USP) has announced revised standards for four ingredients widely used in prescription and over-the-counter drugs. The standards, posted on the USP Web site, include new tests for identifying two harmful and potentially deadly contaminants in the four pharmaceutical excipients - inactive ingredients common in medicines for purposes including sweetening agents and solvents.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169369.php">
<title>Chlamydia Service Training For Support Staff - A Success! UK</title>
<link>http://www.medicalnewstoday.com/articles/169369.php</link>
<description><![CDATA[On 14 October 2009, two half-day training sessions were held for support staff involved in the London commissioned chlamydia service. The training was run by the NPA Pharmacy Services team with support from the Terence Higgins Trust.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169240.php">
<title>Women Have Special Concerns With Prescription Medications</title>
<link>http://www.medicalnewstoday.com/articles/169240.php</link>
<description><![CDATA[Most people have taken a prescription medication at one time or another, but according to a report from the Agency of Healthcare Research and Quality (AHRQ) in Rockville, Md., not only do women take more medications during their lifetimes, women are more likely to suffer from adverse drug events than men.    As a result of this trend: "women should be proactive about their medication use," explains Rosaly Correa-de-Araujo, M.D., M.Sc., Ph.D.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169139.php">
<title>Special Dosage Forms: Educational Event To Take Place In Conjunction With 2009 AAPS Annual Meeting And Exposition</title>
<link>http://www.medicalnewstoday.com/articles/169139.php</link>
<description><![CDATA[ WHO: The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific society of approximately 12,000 members employed in industry, academia, government and other research institutes worldwide. Founded in 1986, AAPS provides a dynamic international forum for the exchange of knowledge among scientists to enhance their contributions to public health.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169127.php">
<title>Nevada Case Raises Question Of Pharmacies&#x27; Liability In Drug Abuse Accidents</title>
<link>http://www.medicalnewstoday.com/articles/169127.php</link>
<description><![CDATA[ A Nevada case causes concern for pharmacies about possible liability for actions taken by customers who may abuse drugs. The Wall Street Journal reports on the case of Patricia Copening, who pleaded guilty to reckless driving after her car swerved off a highway and struck and killed a 21-year-old and injured a 33-year-old. "In Ms.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168946.php">
<title>Texas State Lawmaker Requests Information On Licenses For Dispensing Mifepristone</title>
<link>http://www.medicalnewstoday.com/articles/168946.php</link>
<description><![CDATA[Texas state Rep. Frank Corte (R) earlier this month requested that Texas Attorney General Greg Abbott (R) provide information about whether medical facilities that regularly dispense mifepristone for medical abortion procedures should be licensed by the state, the Fort Worth Star-Telegram reports.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/169004.php">
<title>Policy Recommendations For Improving Medication Adherence</title>
<link>http://www.medicalnewstoday.com/articles/169004.php</link>
<description><![CDATA[A diverse group of health care and consumer organizations released five policy recommendations this week that are designed to promote better medication adherence and improved health outcomes for patients.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168869.php">
<title>AACP Celebrates First-Ever American Pharmacy Educator Week</title>
<link>http://www.medicalnewstoday.com/articles/168869.php</link>
<description><![CDATA[On Oct. 25, 2009, colleges and schools of pharmacy across the country embarked on a week-long national campaign to honor the innovative discoveries and accomplishments of the nation's pharmaceutical scientists and educators. The inaugural American Pharmacy Educator Week, Oct. 25-31, 2009, will promote careers in pharmacy education and urge students to shape the future of tomorrow's healthcare by becoming pharmacy educators.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168830.php">
<title>Guidance On Patient Record Confidentiality, UK</title>
<link>http://www.medicalnewstoday.com/articles/168830.php</link>
<description><![CDATA[A toolkit to help community pharmacies meet their legal and professional requirements to   ensure the confidentiality and security of patient data has been developed collaboratively by   the Royal Pharmaceutical Society of Great Britain (RPSGB), the Pharmaceutical Services   Negotiating Committee (PSNC), the Department of Health and NHS Connecting for Health.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168696.php">
<title>Quality Candidates For National Boards Sought - Royal Pharmaceutical Society Of Great Britain</title>
<link>http://www.medicalnewstoday.com/articles/168696.php</link>
<description><![CDATA[Pharmacists who are passionate about the future of their profession are being urged to step   forward for the National Pharmacy Board elections which start in December.   The Royal Pharmaceutical Society of Great Britain (RPSGB) is asking interested candidates to   ensure their nominations are in by the 23 November closing date.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168531.php">
<title>New Molecules Created By University Of California Riverside Chemists Have Wide Applications</title>
<link>http://www.medicalnewstoday.com/articles/168531.php</link>
<description><![CDATA[ Researchers at the University of California, Riverside have successfully created in the laboratory a class of carbenes, highly reactive molecules, used to make catalysts - substances that facilitate chemical reactions. Until now, chemists believed these carbenes, called "abnormal N-heterocyclic carbenes" or aNHCs, were impossible to make.    Carbenes are made up of unusual carbon atoms and are usually unstable in nature.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168447.php">
<title>PSA Welcomes Progress On Preventive Health, Australia</title>
<link>http://www.medicalnewstoday.com/articles/168447.php</link>
<description><![CDATA[The Pharmaceutical Society of Australia (PSA) has welcomed passage of legislation   through the House of Representatives yesterday that marks a large step forward in   improving the health of Australians. Pending consideration of the legislation in the   Senate, Australia should have its first National Preventive Health Agency ready to   commence activities from 1 January 2010.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168349.php">
<title>Research To Be Presented At The 2009 American Association Of Pharmaceutical Scientists Annual Meeting And Exposition</title>
<link>http://www.medicalnewstoday.com/articles/168349.php</link>
<description><![CDATA[Researchers have developed an optimized mouthpiece design to aid efficient drug delivery to the lungs by reducing the amount of medication wasted as it passes through the mouthpiece of an aerosol inhaler. With current inhaler designs, only approximately 10 to 20 percent of asthma medications are delivered to the lungs.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168316.php">
<title>Transgenic Mouse Models In Drug Metabolism And Transport: Free AAPS Webinar</title>
<link>http://www.medicalnewstoday.com/articles/168316.php</link>
<description><![CDATA[The second part of a two-session series to discuss issues from basic research and drug development perspectives    WHO:  	    The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific society of approximately 12,000 members employed in industry, academia, government and other research institutes worldwide.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168302.php">
<title>Pharmaceutical Company Coupons To Help Patients Buy Drugs May Raise Insurance Premiums</title>
<link>http://www.medicalnewstoday.com/articles/168302.php</link>
<description><![CDATA[ Drug companies use coupons to get patients to choose name-brand products -- which are often more expensive -- by subsidizing a patient's high copay. The practice hides a drug's true costs from consumers. ]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168270.php">
<title>E-Learning Opportunity To Specifically Focus On Trials Of Biologics</title>
<link>http://www.medicalnewstoday.com/articles/168270.php</link>
<description><![CDATA[WHO: The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific society of approximately 12,000 members employed in industry, academia, government and other research institutes worldwide. Founded in 1986, AAPS provides a dynamic international forum for the exchange of knowledge among scientists to enhance their contributions to public health.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168156.php">
<title>Society Urges Registrants Not To Delay Submission Of CPD Records</title>
<link>http://www.medicalnewstoday.com/articles/168156.php</link>
<description><![CDATA[The Royal Pharmaceutical Society of Great Britain is reminding practising pharmacists and   pharmacy technicians that failure to submit their Continuing Professional Development (CPD)   record to the Society when requested to do so is a breach of the Code of Ethics for   Pharmacists and Pharmacy Technicians.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168202.php">
<title>APP Pharmaceuticals Receives Approval For The First Generic Chlorothiazide Sodium For Injection, USP</title>
<link>http://www.medicalnewstoday.com/articles/168202.php</link>
<description><![CDATA[APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. APP expects to launch Chlorothiazide Sodium for Injection, USP in the fourth quarter of 2009.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/168126.php">
<title>Pharmacy Organisations Back H1N1 Swine Flu Vaccine</title>
<link>http://www.medicalnewstoday.com/articles/168126.php</link>
<description><![CDATA[Leading pharmacy organisations today united behind the Department of Health campaign urging pharmacists and other front line health and social care professionals to take up the offer of vaccination against H1N1 swine influenza.   First deliveries of the vaccine will be sent to NHS Acute Trusts from tomorrrow.]]></description>
</item>

<item rdf:about="http://www.medicalnewstoday.com/articles/167938.php">
<title>NPA Raises Profile Of Community Pharmacy At Men&#x27;s Health Conference</title>
<link>http://www.medicalnewstoday.com/articles/167938.php</link>
<description><![CDATA[The National Pharmacy Association highlighted the role community pharmacy services play at the Men's Health Addressing Health Inequalities in the 21st Century conference on Thursday 15 October 2009.    An audience of health professionals, NHS managers and outreach teams heard that the accessibility of community pharmacy provides a platform for health improvement and that many services are suited to men.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189436.htm">
<title>FDA Warns Companies against Marketing Illegal Flavored Cigarettes</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189436.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration is enforcing the flavored cigarette ban provision of the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) by issuing several warning letters to companies continuing to sell illegal flavored cigarettes to consumers in the United States through their Web sites.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189400.htm">
<title>FDA  Health Alert for Certain Pet Treats Made by Pet Carousel</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189400.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration is issuing this health alert to warn consumers not to use Pig Ears and Beef Hooves pet treats manufactured by Pet Carousel because the products may be contaminated with Salmonella. The products were distributed nationwide in both bulk and retail packaging for sale in pet food and retail chain stores. Pet Carousel is based in Sanger, Calif.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189311.htm">
<title>FDA and FSIS Collaborate To Improve Tracing of Unsafe Food Products</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189311.htm</link>
<description><![CDATA[A joint public meeting focused on improving the system for tracing of food products and ingredients that are causing illness outbreaks or presenting other risks to the health of consumers was announced today by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services and the Food Safety and Inspection Service (FSIS) of the U.S. Department of Agriculture (USDA).]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189295.htm">
<title>FDA Warns Consumers on Sexual Enhancement Products</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189295.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration is warning consumers that Stiff Nights, a product marketed as a dietary supplement for sexual enhancement, contains an ingredient that can dangerously lower blood pressure and is illegal.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189081.htm">
<title>FDA Unveils Safe Use Initiative that Targets Preventable Harm from Medication Use</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189081.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration today announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189394.htm">
<title>U.S. Attorney News Release: Doctor Sentenced for Writing Prescriptions Over the Internet for People Whom He Had Never Met or Examined</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189394.htm</link>
<description><![CDATA[A Virginia doctor was sentenced in federal court on charges that he wrote prescriptions over the Internet for people whom he had never met or examined, as well as tax evasion.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188750.htm">
<title>FDA, JIFSAN Travel to Bangladesh to Teach Seafood Safety</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188750.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration and the Joint Institute for Food Safety and Applied Nutrition (JIFSAN) have sent a team of seafood specialists to Bangladesh this week to help train local officials on aquaculture safety and quality control techniques.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188748.htm">
<title>FDA Consumer  Health Information  Updates</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188748.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration (FDA) today released a listing of eight recent consumer health information updates concerning the safety of FDA-regulated products.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188717.htm">
<title>FDA Publishes Guidance on Diagnostic Tests for 2009 H1N1 Influenza Virus</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188717.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration today published a guidance document that should help manufacturers develop diagnostic tests for the 2009 H1N1 influenza virus. Although there are not any FDA-approved or cleared tests that diagnose this specific infection, during this pandemic, manufacturers can submit a request to the FDA for an Emergency Use Authorization (EUA). If granted, the EUA will allow the test to be used during the national public health emergency declared by Department of Health and Human Services Secretary Kathleen Sibelius in April. This guidance document outlines what information the FDA recommends that manufacturers include in these EUA requests.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188715.htm">
<title>FDA Transparency  Task Force to Hold 2nd Public Meeting on Ensuring That Agency Information is Useful, Understandable, Accessible</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188715.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration will seek comments on three specific issues related to transparency at the agency during a daylong public meeting on Tuesday, Nov. 3, 2009.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188708.htm">
<title>FDA: Byetta Label Revised to Include Safety Information on Possible Kidney Problems</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188708.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188543.htm">
<title>FDA: Procter &#x26; Gamble Unlawfully Marketing Two Vicks Cold and Flu Medicines Containing Vitamin C</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188543.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration today sent a warning letter to Procter & Gamble notifying the company that its Vicks DayQuil Plus Vitamin C and Vicks Nyquil Plus Vitamin C are illegally marketed combinations of drug ingredients and a dietary ingredient.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188768.htm">
<title>U.S. Attorney News Release: Bellevue Salon Owner Convicted in Connection With Unlicenced Cosmetic Treatments</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188768.htm</link>
<description><![CDATA[XIN HE, aka FAITH HE, 46, of Issaquah, Washington, was found guilty today in U.S. District Court in Seattle of a felony count of Misbranding of a Drug While Held for Sale and two misdemeanor counts of Receipt & Proffered Delivery of Adulterated Device. HE was ordered into immediate custody by U.S. District Judge Marsha J. Pechman after she rendered her verdict.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188776.htm">
<title>U.S. Attorney News Release: Boca Raton Man Convicted in Nutritional Supplement Scam</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188776.htm</link>
<description><![CDATA[Jeffrey H. Sloman, Acting United States Attorney for the Southern District of Florida, David Bourne, Special Agent in Charge, Food and Drug Administration, Office of Criminal Investigations, Daniel W. Auer, Special Agent in Charge, Internal Revenue Service, Criminal Investigation Division, and Henry Gutierrez, Postal Inspector in Charge, U.S. Postal Inspection Service, announce that late yesterday afternoon, a federal jury convicted defendant Frank Sarcona, a/k/a Frank Sarcone, a/k/a Dave Johnson, 57, of Boca Raton, FL, of conspiracy to commit mail, wire fraud, and criminal contempt of court; conspiracy to commit money laundering; and multiple counts of substantive mail fraud, wire fraud, money laundering, misbranding of a food, and criminal contempt of court. Sentencing has been scheduled for January 15, 2010 at 9:00 a.m. before U.S. District Court Judge Kenneth A. Marra.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188374.htm">
<title>FDA and WebMD Expand Consumer Health Information Partnership</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188374.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration and WebMD Health Corp. today announced an expansion of their partnership to provide increased access to FDA’s consumer health information. This second phase of the partnership includes expanded content and multimedia tools at www.webmd.com/fda. WebMD is personalizing FDA health information for consumers with five new online FDA sections that will initially focus on allergies and asthma, children’s health, diabetes, heart health and vitamins and supplements.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188305.htm">
<title>U.S. Attorney News Release: Stryker Biotech and Its Top Management Indicted for Illegal Promotion of Medical Devices Used in Invasive Surgeries</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188305.htm</link>
<description><![CDATA[Stryker Biotech, LLC, a corporation based in Hopkinton, Massachusetts, and its former president, Mark Philip of Lexington, Massachusetts, and its current sales managers, William Heppner of Illinios, David Ard of California, and Jeff Whitaker of North Carolina, were charged today in federal court with participating in a fraudulent marketing scheme of medical devices used during invasive spinal and long bone surgeries. Stryker Biotech and Mark Philip were also charged with making false statements to the United States Food and Drug Administration (“FDA”).]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188266.htm">
<title>Registration Closes Soon for FDA&#x2019;s Second Annual Science Writers Symposium</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm188266.htm</link>
<description><![CDATA[A few spaces remain for the U.S. Food and Drug Administration’s Second Annual Science Writers Symposium on Nov. 4-5, 2009.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187966.htm">
<title>FDA Approves New Treatment for Chronic Lymphocytic Leukemia</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187966.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187813.htm">
<title>FDA Authorizes Emergency Use of Intravenous Antiviral Peramivir for 2009 H1N1 Influenza for Certain Patients, Settings</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187813.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration announced today that, in response to a request from the U.S. Centers for Disease Control and Prevention, it has issued an emergency use authorization (EUA) for the investigational antiviral drug peramivir intravenous (IV) in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187174.htm">
<title>FDA Approves New Treatment for Advanced Form of Kidney Cancer</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187174.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm189402.htm">
<title>Jelly Belly Issues Allergy Alert on Undeclared Peanuts in 7.5oz cylinder-style packages of 49 Flavors Jelly Belly jelly beans</title>
<link>http://www.fda.gov/Safety/Recalls/ucm189402.htm</link>
<description><![CDATA[Jelly Belly Candy Company is recalling 7.5-ounce cylinder-style packages of 49 Flavors Jelly Belly jelly beans because the package is incorrectly labeled. The mislabeled packages failed to list peanut butter and peanut flour in the ingredient statement...]]></description>
</item>

<item rdf:about="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189400.htm">
<title>FDA  Health Alert for Certain Pet Treats Made by Pet Carousel</title>
<link>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189400.htm</link>
<description><![CDATA[The U.S. Food and Drug Administration is issuing this health alert to warn consumers not to use Pig Ears and Beef Hooves pet treats manufactured by Pet Carousel because the products may be contaminated with Salmonella. The products were distributed nationwide in both bulk and retail packaging for sale in pet food and retail chain stores. Pet Carousel is based in Sanger, Calif.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm189296.htm">
<title>PetSmart Voluntarily Recalls Dentley&#x2019;s Beef Hooves</title>
<link>http://www.fda.gov/Safety/Recalls/ucm189296.htm</link>
<description><![CDATA[PetSmart (NASDAQ: PETM) is voluntarily recalling two Dentley’s Beef Hoof products for potential salmonella contamination. The products were manufactured by Pet Carousel, Inc. in Sanger, Calif.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188981.htm">
<title>Centurion Medical Products - Premie Pack and Meconium Pack - Recall</title>
<link>http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188981.htm</link>
<description><![CDATA[Kits recalled because the pediatric tracheal tubes were manufactured with an internal diameter smaller than indicated on the label.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm188971.htm">
<title>Charleston Cookie Company Issues Allergy Alert on Undeclared Butter in Almond Cookies Produced for Dean &#x26; Deluca</title>
<link>http://www.fda.gov/Safety/Recalls/ucm188971.htm</link>
<description><![CDATA[Charleston Cookie Company of Charleston, SC is recalling packages of Almond Cookies which were sold as a component of the Dean and Deluca "Americana" cookie tin because the cookies contain undeclared butter (milk).]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm188954.htm">
<title>American Regent Expands Voluntary Recall to Include All Lots of Ketorolac Tromethamine Injection, USP 15 mg/mL; 1mL Single Dose Vials</title>
<link>http://www.fda.gov/Safety/Recalls/ucm188954.htm</link>
<description><![CDATA[American Regent conducts nationwide voluntary recall of  ALL lots of its Ketorolac Tromethamine Injection, USP 15 mg/mL:
         NDC# 0517-0601-25     15 mg/mL       1mL Single Dose Vial
PLEASE NOTE:  This recall is in addition to the voluntary recall initiated on October 16, 2009 when American Regent voluntarily recalled ALL unexpired lots of Ketorolac Tromethamine Injection, USP, 30 mg/mL due to the presence of particulate matter in conjunction with crystallization.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm188912.htm">
<title>Pelican Bay Ltd. Issues Nationwide Allergy Alert on Undeclared Tree Nuts in Caramel Chocolate Truffle Hot Chocolate Mix</title>
<link>http://www.fda.gov/Safety/Recalls/ucm188912.htm</link>
<description><![CDATA[Pelican Bay Ltd. of Dunedin, Florida is recalling all their Caramel Chocolate Truffle Hot Chocolate Mix because it may contain undeclared tree nuts.  People who have an allergy or severe sensitivity to tree nuts run the risk of serious or life-threatening allergic reaction if they consume these products.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm188929.htm">
<title>BODYBUILDING.COM Is Conducting a Voluntary Nationwide and International Recall of 65 Dietary Supplements That May Contain Steroids</title>
<link>http://www.fda.gov/Safety/Recalls/ucm188929.htm</link>
<description><![CDATA[As part of its ongoing
cooperation with the Food and Drug Administration (“FDA”), Bodybuilding.com, LLC (the
“Company”) announced today that it is conducting a voluntary nationwide and international
recall of all lots and expiration dates of 65 dietary supplement products (the “Recalled Products”)
described on the attached list, that were sold through the Company’s website,
www.bodybuilding.com.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm188578.htm">
<title>Allergy Alert on Possible  Undeclared Soy Protein in32-ounce Great Value Half &#x26;amp;  Half, 32-ounce Great Value 36% Heavy Whipping Cream, 32-ounce Kroger brand 36% Heavy  Whipping Cream, and 64-ounce Wholesome Farms Chocolate Ice Cream Mix</title>
<link>http://www.fda.gov/Safety/Recalls/ucm188578.htm</link>
<description><![CDATA[Morningstar Foods is voluntarily recalling 32-ounce Great Value Half & Half, UPC  6 05388 187 16 1, item code 1871600, plant code 21-031; 32-ounce Great Value 36% Heavy Whipping Cream, UPC  6 05388 187 18 5, item code 1871800, plant code 21-031; 32-ounce Kroger brand 36% Heavy Whipping Cream, UPC  0 11110 438 28 7, item code 4382900, plant code 21-031; and 64-ounce Wholesome Farms Chocolate Ice Cream Mix, UPC  0 74865 57 983 4 (if purchased in a multi-pack, the UPC code is 1 00 74865 57983 1), item code 5798300, plant code 21-031 because these products may contain soy protein.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm188570.htm">
<title>Alexia Foods issues nationwide allergy alert and product recall on its Alexia Olive Oil, Sun-Dried Tomatoes &#x26; Pesto Oven Reds frozen potatoes due to undeclared pine nut allergen</title>
<link>http://www.fda.gov/Safety/Recalls/ucm188570.htm</link>
<description><![CDATA[Today, Alexia Foods, Inc, Kennewick, WA, in cooperation with the U.S. Food and Drug Administration (FDA) is voluntarily recalling packages of its Alexia – Olive Oil, Sun-Dried Tomatoes & Pesto Oven Reds (frozen seasoned potato wedges) for an undeclared allergen, pine nuts. People who have an allergy or severe sensitivity to pine nuts run the risk of serious or life-threatening allergic reaction if they consume these products.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm188628.htm">
<title>Pointe Scientific, Inc Expands Nationwide Recall of Liquid Glucose Hexokinase Reagent (G7517)</title>
<link>http://www.fda.gov/Safety/Recalls/ucm188628.htm</link>
<description><![CDATA[Pointe Scientific, Inc, Canton, MI is initiating a nationwide recall of all size kits of Liquid Glucose Hexokinase Reagent catalog number G7517.  The reagents have been found to fail linearity at >200mg/dL that results in inaccurate glucose values above this range.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188562.htm">
<title>Pointe Scientific Liquid Glucose Hexokinase Reagent  - Recall</title>
<link>http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188562.htm</link>
<description><![CDATA[Nationwide recall of all size kits. The reagents have been found to fail linearity at >200mg/dL that results in inaccurate glucose values above this range.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm188321.htm">
<title>Cordis Initiates Nationwide Recall of CROSSOVER&#x2122; Sheath Introducer</title>
<link>http://www.fda.gov/Safety/Recalls/ucm188321.htm</link>
<description><![CDATA[Cordis Corporation announced today a nationwide voluntary recall of all lots of the CROSSOVER™ Sheath Introducer due to complaints about stretching or fracture of the sheath during use.  

 

The CROSSOVER™ Sheath Introducer is a product developed and manufactured by Thomas Medical Products, Inc., and distributed by Cordis.  It is a long-coil reinforced, kink-resistant catheter sheath intended for use in arterial and venous procedures requiring the percutaneous, or through the skin, introduction of therapeutic or diagnostic intravascular devices or fluids]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm188521.htm">
<title>Pointe Scientific, Inc Issues Nationwide Recall of Liquid Glucose Hexokinase Reagent (G7517)</title>
<link>http://www.fda.gov/Safety/Recalls/ucm188521.htm</link>
<description><![CDATA[Pointe Scientific, Inc, Canton, MI is initiating a nationwide recall of all size kits of  Liquid Glucose Hexokinase Reagent catalog number G7517.  The reagents have been found to fail linearity at >200mg/dL that results in inaccurate glucose values above this range.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm188318.htm">
<title>Mrs. Rios Corn Products Issues Allergy Alert on Undeclared Whey in Flour Tortillas</title>
<link>http://www.fda.gov/Safety/Recalls/ucm188318.htm</link>
<description><![CDATA[Mrs. Rios Corn Products in San Angelo, Texas is recalling its flour tortillas because they may contain undeclared Whey.  People who have an allergy or severe sensitivity to Whey run the risk of serious or life-threatening allergic reaction if they consume these products.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm188156.htm">
<title>Pop&#x2019;s Bakery Inc. Issues Allergy on Undeclared Whey (Milk) in all Flour Tortillas</title>
<link>http://www.fda.gov/Safety/Recalls/ucm188156.htm</link>
<description><![CDATA[These products may contain undeclared whey (milk). People who have an allergy or severe sensitivity to whey (milk) run the risk of serious or life-threatening allergic reaction if they consume these products.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm188137.htm">
<title>Qualitest Pharmaceuticals Issues a Voluntary Nationwide Recall of All Accusure&#xAE; Insulin Syringes</title>
<link>http://www.fda.gov/Safety/Recalls/ucm188137.htm</link>
<description><![CDATA[Huntsville AL-Qualitest Pharmaceuticals today issued a voluntary nationwide recall of all Accusure® Insulin Syringes. The distributed syringes are of the following descriptions and NDC numbers: 28G 1/2cc, NDC 0603-6995-21;28G 1cc, NDC 0603-6996-21; 29G 1/2cc NDC 0603-6997-21, 29G 1cc, NDC 0603-6998-21, 30G 1/2cc, NDC 0603-999-21, 30G 1cc, NDC 0603-7000-21, 31G 1/2cc, NDC 0603-7001-21, 31G 1cc, NDC 0603-7002-21. All Accusure® Insulin Syringes regardless of lot number are subject to this recall. These syringes were distributed between January 2002 and October 2009 to wholesale and retail pharmacies nationwide (including Puerto Rico). The syringes in these lots may have needles which detach from the syringe.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm187979.htm">
<title>San Link Inc. Issues an Alert on Uneviscerated Vacuum Pack Dried Lesh (Fish).</title>
<link>http://www.fda.gov/Safety/Recalls/ucm187979.htm</link>
<description><![CDATA[San Link Inc at 54B Marjorie Street Staten Island, NY 10309 is recalling Vacuum Pack Dried Lesh (fish) because the product was found to be uneviscerated.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm187973.htm">
<title>San Link Inc. Issues an Alert on Uneviscerated Vacuum Pack Dried Krasnoperka (Fish).</title>
<link>http://www.fda.gov/Safety/Recalls/ucm187973.htm</link>
<description><![CDATA[San Link Inc at 54B Marjorie Street Staten Island, NY 10309 is recalling Vacuum Pack Dried Krasnoperka (fish) because the product was found to be uneviscerated.]]></description>
</item>

<item rdf:about="http://www.fda.gov/Safety/Recalls/ucm187949.htm">
<title>Mars Snackfood US ISSUES ALLERGY ALERT ON UNDECLARED PEANUTS In Dove Caramel Pecan Perfection Ice Cream</title>
<link>http://www.fda.gov/Safety/Recalls/ucm187949.htm</link>
<description><![CDATA[Today, Mars Snackfood US announced a voluntary recall of its Dove Caramel Pecan Perfection ice cream with the lot number 931AB5YN07 because it may contain undeclared peanuts. People who have an allergy or severe sensitivity to peanuts run the risk of serious or life-threatening allergic reaction if they consume these products. No related illnesses have been reported to date.]]></description>
</item>

</rdf:RDF>